Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015, Article ID 324841, 10 pages
http://dx.doi.org/10.1155/2015/324841
Clinical Study

Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

1Department of Specialized Surgical Sciences, Eye Clinic, University of Florence, 50121 Florence, Italy
2Department of Ophthalmology, University Vita-Salute Scientific Institute, San Raffaele, Via Olgettina, 20132 Milan, Italy
3A.O.R.N.A. Cardarelli, 80131 Naples, Italy
4UOSD Patologie Retiniche, Fondazione PTV, Università di Roma Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
5A.O. Polo Universitario Luigi Sacco, Università degli Studi, Grassi 74, 20156 Milan, Italy
6U.O. Oculistica, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università di Milano, 20122 Milan, Italy
7Novartis Farma S.p.A, 21040 Origgio, Italy
8Clinica Oculistica, DiNOGMI, Università di Genova, IRCCS Azienda Ospedaliera Universitaria “San Martino-IST”, 16132 Genova, Italy
9Fondazione per la Macula Onlus, 16121 Genova, Italy

Received 3 March 2015; Accepted 30 May 2015

Academic Editor: Miguel Cordero-Coma

Copyright © 2015 Ugo Menchini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ding and T. Y. Wong, “Current epidemiology of diabetic retinopathy and diabetic macular edema,” Current Diabetes Reports, vol. 12, no. 4, pp. 346–354, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Chen, M. Looman, M. Laouri et al., “Burden of illness of diabetic macular edema: literature review,” Current Medical Research & Opinion, vol. 26, no. 7, pp. 1587–1597, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 4th edition, 2009.
  4. A. M. Bron, A. C. Viswanathan, U. Thelen et al., “International vision requirements for driver licensing and disability pensions: using a milestone approach in characterization of progressive eye disease,” Clinical Ophthalmology, vol. 4, no. 1, pp. 1361–1369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Giuffrè, G. Lodato, and G. Dardanoni, “Prevalence and risk factors of diabetic retinopathy in adult and elderly subjects: the Casteldaccia Eye Study,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 242, no. 7, pp. 535–540, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. Early Treatment Diabetic Retinopathy Study Research Group, “Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2,” Ophthalmology, vol. 94, no. 7, pp. 761–774, 1987. View at Publisher · View at Google Scholar · View at Scopus
  7. N. M. Bressler, A. R. Edwards, R. W. Beck et al., “Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation,” Archives of Ophthalmology, vol. 127, no. 12, pp. 1566–1571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. A. H. Laidlaw, “Vitrectomy for diabetic macular oedema,” Eye, vol. 22, no. 10, pp. 1337–1341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Lövestam-Adrian and E. Agardh, “Photocoagulation of diabetic macular oedema-complications and visual outcome,” Acta Ophthalmologica Scandinavica, vol. 78, no. 6, pp. 667–671, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim, “Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration,” Retina, vol. 26, no. 8, pp. 859–870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al., “The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 615–625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Elman, L. P. Aiello, R. W. Beck et al., “Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,” Ophthalmology, vol. 117, no. 6, pp. 1064.e35–1077.e35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. J. Elman, N. M. Bressler, H. Qin et al., “Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema,” Ophthalmology, vol. 118, no. 4, pp. 609–614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. J. Elman, H. Qin, L. P. Aiello et al., “Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized study results,” Ophthalmology, vol. 119, no. 11, pp. 2312–2318, 2012. View at Publisher · View at Google Scholar
  15. Q. D. Nguyen, S. M. Shah, J. S. Heier et al., “Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study,” Ophthalmology, vol. 116, no. 11, pp. 2175–2181.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Massin, F. Bandello, J. G. Garweg et al., “Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study,” Diabetes Care, vol. 33, no. 11, pp. 2399–2405, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. U. Schmidt-Erfurth, G. E. Lang, F. G. Holz et al., “Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study,” Ophthalmology, vol. 121, no. 5, pp. 1045–1053, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. G. E. Lang, A. Berta, B. M. Eldem et al., “Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the restore extension study,” Ophthalmology, vol. 120, no. 10, pp. 2004–2012, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. Q. D. Nguyen, D. M. Brown, D. M. Marcus et al., “Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE,” Ophthalmology, vol. 119, no. 4, pp. 789–801, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (LRT for DME), https://clinicaltrials.gov/ct2/show/results/NCT00444600.
  21. 2014, https://www.medicines.org.uk/emc/medicine/19409.
  22. I. Pearce, S. Banerjee, B. J. L. Burton et al., “Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase IIIB RELIGHT study,” Opthalmology, 2015. View at Publisher · View at Google Scholar
  23. C. Pruente, “RETAIN: 24-month safety & efficacy of ranibizumab in DME under a treat & extend treatment regimen,” in Proceedings of the ARVO Annual Meeting, Abstract 1917169, Orlando, Fla, USA, May 2014.